Monoclonal antibodies have revolutionized modern medicine. However, antibodies are delicate molecules that can aggregate to form potentially harmful particulates. Having been studied mostly empirically, the formation of proteinaceous particles remains a major obstacle for the development of safe therapeutic proteins. My project aims to address the phenomenon at different states between early drug development and in-hospital handling to allow safer treatments. I will achieve my goal by (1) exploring correlations between the physicochemical properties of 30+ model antibodies and properties of the particles formed by these antibodies due to mechanical stress to find what antibody properties are causative for particle formation in the clinic, (2) developing novel methods to detect and analyze protein aggregates in the analytically challenging size range (0.1-10 µm), and (3) drafting general guidelines and strategies for antibody handling in the clinic to improve the safety of available treatments. Therefore, my project is highly relevant for the biopharmaceutical sector and for the millions of patients that need safe and particle-free biotherapeutics.